
Gilead and Lakefront Complete $1.675 Billion Ouro Medicines Acquisition
Ravi IyerGilead Sciences (Nasdaq: GILD) and Lakefront Biotherapeutics (Euronext and Nasdaq: LKFT) completed the acquisition of Ouro Medicines on June 4, 2026, with Gilead paying $1,675 million for all outstanding equity plus up to $500 million in contingent milestone payments, per the company's announcement.




